Coronary artery stents revolutionized the practice of interventional cardiology after they were first introduced in the mid-1980s. Since then, there have been significant developments in their design, the most notable of which has been the introduction of drug-eluting stents. This paper reviews the benefits, risks, and current status of Food and Drug Administration-approved drug-eluting stents.

bare-metal stents, clopidogrel, cost-effectiveness, diabetes, drug-eluting stents, everolimus-eluting stents, left main disease, myocardial infarction, paclitaxel-eluting stents, restenosis, saphenous vein grafts, sirolimus-eluting stents, stent fracture, stent thrombosis, zotarolimus-eluting stents,
Journal of the American College of Cardiology
Erasmus MC: University Medical Center Rotterdam

Garg, S.A, & Serruys, P.W.J.C. (2010). Coronary stents: Current status. Journal of the American College of Cardiology (Vol. 56). doi:10.1016/j.jacc.2010.06.007